Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Ipilimumab (Primary) ; Paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Oct 2020 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 04 Jun 2019 Results (n=18) presented at the 55th Annual Meeting of the American Society of Clinical Oncology